Targeting histone methyltransferase EZH2 as cancer treatment.
about
Emerging players in prostate cancer: long non-coding RNAsEZH2 in Bladder Cancer, a Promising Therapeutic TargetEpigenome-based personalized medicine in human cancerAn integrative pan-cancer-wide analysis of epigenetic enzymes reveals universal patterns of epigenomic deregulation in cancerLATS2 Positively Regulates Polycomb Repressive Complex 2.A novel MeCP2 acetylation site regulates interaction with ATRX and HDAC1.The Polycomb Group Protein EZH2 Impairs DNA Damage Repair Gene Expression in Human Uterine FibroidsThe relationship between EZH2 expression and microRNA-31 in colorectal cancer and the role in evolution of the serrated pathwayIntegrated bioinformatics analysis of chromatin regulator EZH2 in regulating mRNA and lncRNA expression by ChIP sequencing and RNA sequencing.The role of polycomb repressive complexes in biliary tract cancer.Transcription factors that interact with p53 and Mdm2Predicting the Correlation of EZH2 and Cancer Stem Cell Markers in Esophageal Squamous Cell Carcinoma.Inhibition of S-Adenosylmethionine-Dependent Methyltransferase Attenuates TGFβ1-Induced EMT and Metastasis in Pancreatic Cancer: Putative Roles of miR-663a and miR-4787-5p.Structure of the PRC2 complex and application to drug discovery.Identification of Polycomb Group Protein EZH2-Mediated DNA Mismatch Repair Gene MSH2 in Human Uterine Fibroids.The histone methyltransferase EZH2 as a druggable target in SHH medulloblastoma cancer stem cells.A Proof-of-Concept for Epigenetic Therapy of Tissue Fibrosis: Inhibition of Liver Fibrosis Progression by 3-Deazaneplanocin A.Stromal cells in phyllodes tumors of the breast are enriched for EZH2 and stem cell marker expression.Crosstalk Between Histone and DNA Methylation in Regulation of Retinal Matrix Metalloproteinase-9 in Diabetes.EZH2 alteration driven by microRNA-524-5p and microRNA-324-5p promotes cell proliferation and temozolomide resistance in glioma.EZH2 Overexpression as a Useful Prognostic Marker for Aggressive Behaviour in Thyroid Cancer.Upregulation of histone-lysine methyltransferases plays a causal role in hexavalent chromium-induced cancer stem cell-like property and cell transformation.Epigenetic Silencing of miRNA-34a in Human Cholangiocarcinoma via EZH2 and DNA Methylation: Impact on Regulation of Notch Pathway.The polycomb group protein EZH2 induces epithelial-mesenchymal transition and pluripotent phenotype of gastric cancer cells by binding to PTEN promoter.Clinicopathological features of primary diffuse large B-cell lymphoma of the central nervous system - strong EZH2 expression implying diagnostic and therapeutic implication.Melatonin inhibits tumorigenicity of glioblastoma stem-like cells via the AKT-EZH2-STAT3 signaling axis.Protein phosphatase PP1-NIPP1 activates mesenchymal genes in HeLa cells.
P2860
Q26853712-624C18EE-A50D-489D-86EC-D88B22F99E5BQ28082054-4E677AC0-519F-4F9F-A576-7FB32FC57DAAQ28083951-18E56BF7-51C7-432A-AC05-D1C0871F6B91Q35848254-A3F0E35C-D6D0-4B35-8808-1614C14BA0D8Q36081710-90749C53-8B81-4E3B-ACA0-1C86AFB59950Q36248469-1E9E4FB7-B384-495A-AD09-231D9B227EABQ36791100-42D2B452-D427-434E-AF68-4835100E2DEDQ37022273-638D9294-C675-4D08-BAED-FC3F1083B0F6Q37697207-932061D7-584A-4D15-A40C-F3C960BBA54EQ38271374-49041F3F-7BF2-47DA-A42D-5FF36A17DC00Q38541481-E0B46B59-5F05-4BC8-A4D5-A29301774344Q38691864-DA4D9096-B342-4355-9C03-137F07D1A117Q38733932-B2536319-401C-4709-9C6B-4FAE5436F3DAQ39245946-E85E6FAC-277D-4E07-8D97-9174379375AFQ39870818-909D4928-7B68-43EC-9C0B-028C9D55230BQ42366629-8992F6EA-2141-48A1-9086-65E10AEFC6BBQ45864008-93891D3A-D60A-4E82-ADF7-75E4B87A803DQ46116571-C1DD1C42-E87B-4588-9B68-9D0305ACED36Q47122605-ED2DF9C5-AF87-4180-B742-972F336B50BEQ47140497-74E8D2F3-5F1C-4825-A7C5-12F6281B90DFQ47257495-323D3221-B8A3-4AC7-93BA-7BB557016F71Q47640099-D01398AE-85D5-472E-8591-4FB713D002F0Q47783721-F1354902-238C-4E5E-B2D1-D540A289B42FQ49599642-46D7BE3E-6987-47A5-962A-F11AE6F6421CQ51347784-3B39F9B9-44AA-485A-968A-37CEB300D17BQ53113443-84B18ED4-DCE3-41F6-8045-A924C2669791Q55059073-F3C3C4C0-42B7-42B2-ADBB-25D157D0039D
P2860
Targeting histone methyltransferase EZH2 as cancer treatment.
description
2014 nî lūn-bûn
@nan
2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Targeting histone methyltransferase EZH2 as cancer treatment.
@ast
Targeting histone methyltransferase EZH2 as cancer treatment.
@en
type
label
Targeting histone methyltransferase EZH2 as cancer treatment.
@ast
Targeting histone methyltransferase EZH2 as cancer treatment.
@en
prefLabel
Targeting histone methyltransferase EZH2 as cancer treatment.
@ast
Targeting histone methyltransferase EZH2 as cancer treatment.
@en
P2860
P356
P1476
Targeting histone methyltransferase EZH2 as cancer treatment.
@en
P2093
Yutaka Kondo
P2860
P304
P356
10.1093/JB/MVU054
P577
2014-08-31T00:00:00Z